A Multicenter Phase II Study of Subcutaneous Velcade Plus Oral Melphalan and Prdnisone or Plus Cycloposphamide and Prednisone or Plus Prednisone in Newly Diagnosed Elderly Multiple Myeloma Patients.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 Aug 2018 Planned End Date changed from 1 May 2019 to 1 May 2020.
- 09 May 2016 Planned End Date changed from 1 May 2016 to 1 May 2019.
- 24 Mar 2015 Planned End Date changed from 1 Aug 2015 to 1 May 2016 as reported by ClinicalTrials.gov